After less than a year on the job, the head of FDA’s Office of Generic Drugs (OGD) has announced his departure, a sign that all is not well with plans for major organizational changes at the Center for Drug Evaluation and Research (CDER).
Posted in FDA, Legal, leadership | Also tagged ANDA, CDER, chemistry and manufacturing controls, CMC, generics, Janet Woodcock, Office of Pharmaceutical Quality, OGD, OPQ
PharmExec Blog
Follow Us
RSS
Bookstore
CDER Runs into Trouble with Generic Drug Reorg Plan